The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Open accessAbstract
Aggregation of biotherapeutics has the potential to induce an immunogenic response. Here, we show that aggregated therapeutic antibodies, previously generated and determined to contain a variety of attributes (Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., and Narhi, L. O. (2011) J. Biol. Chem. 286, 25118-25133), can enhance the in vitro innate immune response of a population of naive human peripheral blood mononuclear cells. This response depended on the aggregate type, inherent immunogenicity of the monomer, and donor responsiveness, and required a high number of particles, well above that detected in marketed drug products, at least in this in vitro system. We propose a cytokine signature as a potential biomarker of the in vitro peripheral blood mononuclear cell response to aggregates. The cytokines include IL-1β, IL-6, IL-10, MCP-1, MIP-1α, MIP-1β, MMP-2, and TNF-α. IL-6 and IL-10 might have an immunosuppressive effect on the long term immune response. Aggregates made by stirring induced the highest response compared with aggregates made by other methods. Particle size in the 2-10 μm range and the retention of some folded structure were associated with an increased response. The mechanism of aggregate activation at the innate phase was found to occur through specific cell surface receptors (the toll-like receptors TLR-2 and TLR-4, FcγRs, and the complement system). The innate signal was shown to progress to an adaptive T-cell response characterized by T-cell proliferation and secretion of T-cell cytokines. Investigating the ability of aggregates to induce cytokine signatures as biomarkers of immune responses is essential for determining their risk of immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors
Brightbill, H. D., Libraty, D. H., Krutzik, S. R., Yang, R.-B., Belisle, J. T., Bleharski, J. R., Maitland, M., Norgard, M. V., Plevy, S. E., Smale, S. T., et al. (1999) · Science · doi:10.1126/science.285.5428.732 · Cited by 1,661
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., & Plebanski, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3148 · Cited by 664
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators
Tilg, H., Dinarello, C. A., & Mier, J. W. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01103-1 · Cited by 633
Pathogen recognition and development of particulate vaccines: Does size matter?
Xiang, S. D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P. L., & Plebanski, M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.016 · Cited by 602
Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Russell Middaugh, C., Winter, G., Fan, Y.-X., Kirshner, S., Verthelyi, D., Kozlowski, S., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21530 · Cited by 595
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Bioequivalence and the immunogenicity of biopharmaceuticals
Schellekens, H. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd818 · Cited by 534
Friendly and dangerous signals: is the tissue in control?
Matzinger, P. (2007) · Nature Immunology · doi:10.1038/ni0107-11 · Cited by 532
NEUTRALIZING ANTIVIRAL B CELL RESPONSES
Bachmann, M. F., & Zinkernagel, R. M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.235 · Cited by 471
TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells
Krutzik, S. R., Tan, B., Li, H., Ochoa, M. T., Liu, P. T., Sharfstein, S. E., Graeber, T. G., Sieling, P. A., Liu, Y.-J., Rea, T. H., et al. (2005) · Nature Medicine · doi:10.1038/nm1246 · Cited by 404
Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody
Kiese, S., Papppenberger, A., Friess, W., & Mahler, H.-C. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21328 · Cited by 397
Microbial Lipopeptides Stimulate Dendritic Cell Maturation Via Toll-Like Receptor 2
Hertz, C. J., Kiertscher, S. M., Godowski, P. J., Bouis, D. A., Norgard, M. V., Roth, M. D., & Modlin, R. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2444 · Cited by 356
Lin, Y., Lee, H., Berg, A. H., Lisanti, M. P., Shapiro, L., & Scherer, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002137200 · Cited by 355
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Strategies for the assessment of protein aggregates in pharmaceutical biotech product development
den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., Seidl, A., Hainzl, O., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0297-1 · Cited by 348
Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22097 · Cited by 334
Self-citationClassification and Characterization of Therapeutic Antibody Aggregates
Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., & Narhi, L. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160457 · Cited by 316
Self-citationBraun, A., Kwee, L., Labow, M. A., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 298
Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro
Morefield, G. L., Sokolovska, A., Jiang, D., HogenEsch, H., Robinson, J. P., & Hem, S. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.07.050 · Cited by 293
Canfield, S. M., & Morrison, S. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1483 · Cited by 266
Higgins, S. C., Lavelle, E. C., McCann, C., Keogh, B., McNeela, E., Byrne, P., O’Gorman, B., Jarnicki, A., McGuirk, P., & Mills, K. H. G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3119 · Cited by 265
Antibody-based therapeutics to watch in 2011
Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.1.13895 · Cited by 236
Corry, D. B., Kiss, A., Song, L.-Z., Song, L., Xu, J., Lee, S.-H., Werb, Z., & Kheradmand, F. (2004) · The FASEB Journal · doi:10.1096/fj.03-1412fje · Cited by 209
FcγRIII Mediates Neutrophil Recruitment to Immune Complexes
Coxon, A., Cullere, X., Knight, S., Sethi, S., Wakelin, M. W., Stavrakis, G., Luscinskas, F. W., & Mayadas, T. N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00150-9 · Cited by 206
Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions
Luo, Q., Joubert, M. K., Stevenson, R., Ketchem, R. R., Narhi, L. O., & Wypych, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160440 · Cited by 199
Self-citationHermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185
Immunogenicity of aggregates of recombinant human growth hormone in mouse models
Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21834 · Cited by 170
Immunogenicity of therapeutic proteins: the use of animal models
Brinks, V., Jiskoot, W., & Schellekens, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0523-5 · Cited by 164
A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals
Maas, C., Hermeling, S., Bouma, B., Jiskoot, W., & Gebbink, M. F. B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605984200 · Cited by 163
Grasenick, K., & Low, J. (2004) · Journal of Intellectual Capital · doi:10.1108/14691930410533696 · Cited by 162
Immunogenicity of therapeutic proteins
Schellekens, H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg164 · Cited by 148
Hermeling, S., Caetano, L. A., Damen, M. J. A., Slijper, M., Schellekens, H., Crommelin, D. J. A., & Jiskoot, W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8177-9 · Cited by 144
Prior, S., Gander, B., Blarer, N., Merkle, H. P., Subirá, M. L., Irache, J. M., & Gamazo, C. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00218-4 · Cited by 138
Denis, J., Majeau, N., Acosta‐Ramírez, E., Savard, C., Bédard, M.-C., Simard, S., Lecours, K., Bolduc, M., Paré, C., Willems, B. E., et al. (2007) · Virology · doi:10.1016/j.virol.2007.01.011 · Cited by 138
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16).
Hazenbos, W. L. W., Heijnen, I., Meyer, D., Hofhuis, F. M., de Lavalette, C. R., Schmidt, R. E., Capel, P. J., van de Winkel, J. G. J., Gessner, J. E., van den Berg, T. K., et al. (1998) · PubMed · Cited by 137
Characterization of the Fc receptor for IgG on a human macrophage cell line, U937.
Anderson, C. L., & Abraham, G. N. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.6.2735 · Cited by 133
Rönnelid, J., Tejde, A., Mathsson, L., Nilsson-Ekdahl, K., & Nilsson, B. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.1.37 · Cited by 130
Murine IgG1 Complexes Trigger Immune Effector Functions Predominantly via FcγRIII (CD16)
Hazenbos, W. L. W., Heijnen, I., Meyer, D., Hofhuis, F. M., de Lavalette, C. R., Schmidt, R. E., Capel, P. J., van de Winkel, J. G. J., Gessner, J. E., van den Berg, T. K., et al. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3026 · Cited by 120
Reipert, B. M., van Helden, P. M., Schwarz, H., & Baumgartner, C. K. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06359.x · Cited by 108
Popi, A. F., Lopes, J. D., & Mariano, M. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01969.x · Cited by 106
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice
Purohit, V. S., Middaugh, C. R., & Balasubramanian, S. V. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20529 · Cited by 92
Wullner, D., Zhou, L., Bramhall, E., Kuck, A. J., Goletz, T. J., Swanson, S. J., Chirmule, N. B., & Jawa, V. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.06.018 · Cited by 91
Self-citationImmediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
Vultaggio, A., Maggi, E., & Matucci, A. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283464bcd · Cited by 74
Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins
Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22683 · Cited by 65
Where disease pathogenesis meets protein formulation: Renal deposition of immunoglobulin aggregates
Demeule, B., Gurny, R., & Arvinte, T. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.08.008 · Cited by 60
Jaber, A., & Baker, M. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.10.023 · Cited by 59
Self-citationPatten, P. A., & Schellekens, H. (2003) · PubMed · Cited by 59
Immunogenicity of rDNA-derived pharmaceuticals
Ryff, J. ‐., & Schellekens, H. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02024-2 · Cited by 54
Perry, L., Jones, T. D., & Baker, M. (2008) · Drugs in R&D · doi:10.2165/0126839-200809060-00004 · Cited by 51
Self-citationMatzinger, P. (2004) · Vox Sanguinis · doi:10.1111/j.1741-6892.2004.00508.x · Cited by 48
Padgett, J. J. (1994) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/0279-3695-19940101-04 · Cited by 47
Babiuk, S., Skowronski, D. M., Serres, G. D., HayGlass, K. T., Brunham, R. C., & Babiuk, L. A. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10540 · Cited by 39
The Rebif® New Formulation Story
Jaber, A., Driebergen, R. J., Giovannoni, G., Schellekens, H., Simsarian, J., & Antonelli, M. (2007) · Drugs in R&D · doi:10.2165/00126839-200708060-00002 · Cited by 35
Iwakura, Y., & Nozaki, M. (1985) · Developmental Biology · doi:10.1016/0012-1606(85)90127-7 · Cited by 30
Correlation of rFVIII Inactivation with Aggregation in Solution
Wang, W., & Kelner, D. N. (2003) · Pharmaceutical Research · doi:10.1023/a:1023271405005 · Cited by 28
Cytokines in human health : immunotoxicology, pathology, and therapeutic applications
House, R. V., & Descotes, J. (2007) · Cited by 27
Magi, M., Garcia, L., Vandenbranden, M., Palmantier, R., & Jacquet, A. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.04.014 · Cited by 21
Cited by
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 529
Self-citationTherapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
Physicochemical Stability of Monoclonal Antibodies: A Review
Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A., & Sautou, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.009 · Cited by 429
Metadata
- Authors
- Joubert, M. K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M. P., Goletz, T. J., Kerwin, B. A., Chirmule, N., Narhi, L. O., & Jawa, V.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 287
- Issue
- 30
- Pages
- 25266-25279
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2048087821
- Cited by
- 268
- References
- 63
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.